Sallman et al. demonstrated that MDS and secondary AML patients with TP53 mutations exhibit elevated PD-L1 expression in HSCs, which is driven by the upregulation of MYC and the downregulation of MYC’s negative regulator miR-34a. Here, TP53 is linked to acute myeloid leukemia.